版本:
中国

BRIEF-Pfizer’s ALK/ROS1 inhibitor granted breakthrough therapy designation from FDA

April 27 Pfizer Inc

* pfizer’s next-generation alk/ros1 inhibitor, lorlatinib, granted breakthrough therapy designation from fda for alk-positive metastatic non-small cell lung cancer

* Pfizer inc says additionally, phase 3 crown study (nct03052608) recently began enrolling patients Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐